Organ Preservation Product
Organ Transplant Preservation (e.g., Heart)
Pre-clinicalActive
Key Facts
Indication
Organ Transplant Preservation (e.g., Heart)
Phase
Pre-clinical
Status
Active
Company
About Theratome Bio
Theratome Bio is a private, pre-revenue biotech company founded in 2018, transitioning from research to commercial focus in 2023. Its core technology involves AI-optimized, second-generation secretomes derived from adult stem cells, engineered for specific disease profiles by enhancing desired components and deleting others. The company's near-term pipeline targets organ transplant preservation and dry eye disease, with a longer-term interest in conditions like ARDS, ALS, and stroke, led by a team with deep expertise in vascular biology and cell therapy.
View full company profile